metformin has been researched along with fenofibrate in 45 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (40.00) | 29.6817 |
2010's | 26 (57.78) | 24.3611 |
2020's | 1 (2.22) | 2.80 |
Authors | Studies |
---|---|
Agarwal, SC; Chander, R; Khaliq, T; Narender, T; Papi Reddy, K; Prathipati, P; Puri, A; Raj, K; Shweta, S; Srivastava, AK; Tiwari, P | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Maurya, R; Singh, AB; Srivastava, AK | 1 |
Narender, T; Papi Reddy, K; Puri, A; Singh, AB; Srivastava, AK | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Tuomilehto, J | 1 |
Alvarez Fidalgo, P; Codoceo, R; Díez, JJ; Iglesias, P | 1 |
Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I | 1 |
Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS | 1 |
Guo, XH; Wang, NH; Wang, W | 1 |
Kastelein, JJ; Nieuwdorp, M; Stroes, ES | 1 |
Abdallah, P; Basset, A; Beylot, M; Bricca, G; Del Carmine, P; Forcheron, F; Metais, C | 1 |
Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
Dieterich, HA; Dole, WP; Howard, D; Maboudian, M; Vaidyanathan, S; Warren, V; Yeh, CM | 1 |
Abdallah, P; Basset, A; Beylot, M; Del Carmine, P; Forcheron, F; Gadot, N | 1 |
Krysiak, R; Okopien, B; Pruski, M | 1 |
Al-Mousawi, AM; Gauglitz, GG; Herndon, DN; Jeschke, MG; Mecott, GA | 1 |
Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G | 1 |
Basset, A; Beylot, M; Del Carmine, P; Forcheron, F | 1 |
Aslanidis, C; Bauer, S; Buechler, C; Luchner, A; Neumeier, M; Schäffler, A; Schnitzbauer, AA; Wanninger, J; Weigert, J | 1 |
Feng, L; Gao, G; Gao, L; Guan, Q; Liu, Y; Wan, Q; Wang, C; Wang, F; Zhao, J | 1 |
Bundrick, JB; Litin, SC | 1 |
Gdula-Dymek, A; Krysiak, R; Okopien, B | 4 |
Colman, PG; Donoghoe, M; Forder, P; Graham, N; Haapamäki, H; Keech, A; Kritharides, L; Merrifield, A; Simes, J; Sullivan, D; Whiting, M | 1 |
Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN | 1 |
Rehman, HU | 1 |
Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY | 1 |
Arnett, TR; Butters, OR; Patel, JJ | 1 |
Lee, WL; Loo, SC; Tan, CN; Tan, JW | 1 |
Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M | 1 |
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
Anabtawi, A; Miles, JM; Moriarty, PM | 1 |
Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A | 1 |
4 review(s) available for metformin and fenofibrate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
The role of hyperglycemia in burned patients: evidence-based studies.
Topics: Blood Glucose; Burns; Fenofibrate; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin | 2010 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2017 |
10 trial(s) available for metformin and fenofibrate
Article | Year |
---|---|
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Treatment Outcome | 2007 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibrinogen; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Placebos; Plasminogen Activator Inhibitor 1; Risk Factors | 2009 |
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Prediabetic State; Young Adult | 2010 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome | 2011 |
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Topics: Administration, Oral; Aged; Australia; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2011 |
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperinsulinism; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Treatment Outcome; Young Adult | 2011 |
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intolerance; Hemostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Single-Blind Method | 2013 |
Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lymphocytes; Male; Metformin; Middle Aged | 2013 |
Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Female; Fenofibrate; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipids; Male; Metformin; Middle Aged; Monocytes; Poland; Time Factors; Treatment Outcome; Young Adult | 2013 |
31 other study(ies) available for metformin and fenofibrate
Article | Year |
---|---|
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aegle; Animals; Blood Glucose; Cholesterol; Cholesterol, HDL; Cricetinae; Diabetes Mellitus, Experimental; Dietary Fats; Fatty Acids, Nonesterified; Hypoglycemic Agents; Hypolipidemic Agents; Male; Models, Molecular; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Metformin; Mice; Mice, Inbred C57BL; Plant Extracts; Rats; Rats, Sprague-Dawley; Withania; Withanolides | 2008 |
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemistry, Pharmaceutical; Cricetinae; Diabetes Mellitus, Experimental; Drug Design; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Models, Chemical; Pentacyclic Triterpenes; Rats; Streptozocin; Triglycerides; Triterpenes | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Flavone-based novel antidiabetic and antidyslipidemic agents.
Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.
Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hormones, Ectopic; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Metformin; Resistin; Tumor Necrosis Factor-alpha; Weight Loss | 2004 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones | 2005 |
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; Metformin; Rats; Rats, Inbred OLETF; Sterol Regulatory Element Binding Protein 1 | 2006 |
[Change in ghrelin level with the amelioration of glucose and lipid metabolic disorder in OLETF rats].
Topics: Animals; Blotting, Northern; Diabetes Mellitus, Type 2; Fenofibrate; Gastric Mucosa; Ghrelin; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Random Allocation; Rats; Rats, Inbred OLETF; RNA, Messenger; Stomach | 2006 |
Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Eating; Fatty Acids, Nonesterified; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; Receptors, Adiponectin; RNA, Messenger; Triglycerides | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Area Under Curve; Chromatography, Liquid; Drug Interactions; Female; Fenofibrate; Fumarates; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Renin; Tandem Mass Spectrometry; Thiazolidinediones | 2008 |
Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.
Topics: Animals; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Experimental; Disease Models, Animal; Fenofibrate; Male; Metformin; Rats; Rats, Zucker | 2009 |
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating; Energy Metabolism; Fatty Acids; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; RNA, Messenger; Triglycerides | 2009 |
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Nonesterified; Fenofibrate; Heart; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Membrane Proteins; Metformin; Myocardium; Obesity; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triglycerides | 2009 |
Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals.
Topics: 3T3-L1 Cells; Adipocytes; Aged; Animals; Diabetes Mellitus; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Intra-Abdominal Fat; Male; Metformin; Mice; Middle Aged; Rats; Rats, Zucker; Receptors, Adiponectin | 2010 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Infective Agents, Urinary; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diagnosis, Differential; Female; Fenofibrate; Gout; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Internal Medicine; Losartan; Male; Metformin; Nifedipine; Potassium; Sulfonamides; Tamsulosin; Trimethoprim; Ureteral Calculi; Vitamin B 12 Deficiency | 2011 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2012 |
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Feeding Behavior; Fenofibrate; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Immunohistochemistry; Injections, Intraperitoneal; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Peptides; Rats; Receptors, Glucagon; Venoms | 2013 |
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Modulating drug release from gastric-floating microcapsules through spray-coating layers.
Topics: Capsules; Coated Materials, Biocompatible; Delayed-Action Preparations; Fenofibrate; Half-Life; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Piroxicam | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glucose Intolerance; Humans; Infant; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Metabolome; Metformin; Pituitary Neoplasms; Retrospective Studies | 2015 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin | 2022 |